Simon Quick Advisors LLC Invests $54,000 in Standard BioTools Inc. (NASDAQ:LAB)

Simon Quick Advisors LLC acquired a new position in Standard BioTools Inc. (NASDAQ:LAB) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 31,091 shares of the company’s stock, valued at approximately $54,000.

Other large investors have also recently modified their holdings of the company. Wolverine Trading LLC acquired a new position in shares of Standard BioTools during the third quarter worth $27,000. Xponance Inc. acquired a new position in Standard BioTools during the 2nd quarter valued at about $34,000. Nisa Investment Advisors LLC increased its position in Standard BioTools by 433.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock valued at $35,000 after buying an additional 14,732 shares in the last quarter. Creative Planning purchased a new stake in Standard BioTools in the third quarter valued at about $39,000. Finally, Algert Global LLC purchased a new stake in shares of Standard BioTools during the second quarter worth about $44,000. Institutional investors own 53.74% of the company’s stock.

Wall Street Analyst Weigh In

Separately, TD Cowen decreased their price objective on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research report on Thursday, October 31st.

Standard BioTools Price Performance

Shares of LAB stock opened at $1.65 on Friday. The business has a fifty day moving average of $1.82 and a 200 day moving average of $1.90. Standard BioTools Inc. has a 1 year low of $1.21 and a 1 year high of $3.04. The firm has a market capitalization of $614.23 million, a price-to-earnings ratio of -2.32 and a beta of 1.57.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.